Vulvodynia; an under-recognized disease by Georgescu, Simona Roxana et al.
Journal of Mind and Medical Sciences
Volume 3 | Issue 2 Article 6
2016
Vulvodynia; an under-recognized disease
Simona Roxana Georgescu
Carol Davila University, Department of Dermatology and Venereology, simonaroxanageorgescu@yahoo.com
Cristina I. Mitran
Victor Babes Hospital, Department of Dermatology and Venereology
Mădălina I. Mitran
Victor Babes Hospital, Department of Dermatology and Venereology
Maria I. Sârbu
Carol Davila University, Department of Dermatology and Venereology
Mircea Tampa
Carol Davila University, Department of Dermatology and Venereology
Follow this and additional works at: http://scholar.valpo.edu/jmms
Part of the Female Urogenital Diseases and Pregnancy Complications Commons, Marriage and
Family Therapy and Counseling Commons, Obstetrics and Gynecology Commons, Reproductive
and Urinary Physiology Commons, and the Women's Health Commons
This Review Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in Journal of Mind and Medical
Sciences by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at scholar@valpo.edu.
Recommended Citation
Georgescu, Simona Roxana; Mitran, Cristina I.; Mitran, Mădălina I.; Sârbu, Maria I.; and Tampa, Mircea (2016) "Vulvodynia; an
under-recognized disease," Journal of Mind and Medical Sciences: Vol. 3 : Iss. 2 , Article 6.
Available at: http://scholar.valpo.edu/jmms/vol3/iss2/6
J Mind Med Sci. 2016; 3(2): 141-149.  Review Article 
 
 
 
 Corresponding author: Simona R. Georgescu, MD, PhD., Victor Babes Hospital for Infectious and Tropical Diseases, 
Sos. Mihai Bravu 283, 3rd District, 030303, Bucharest, Romania; e-mail: simonaroxanageorgescu@yahoo.com  
 
 
 
Vulvodynia; an under-recognized disease 
 
1,2Simona R. Georgescu, 2Cristina I. Mitran, 2Mădălina I. Mitran, 1,2Maria I. Sârbu, 
1,2Mircea Tampa  
1Carol Davila University, Department of Dermatology and Venereology, 2Victor Babes Hospital for Infectious and Tropical 
Diseases, Department of Dermatology and Venereology 
 
 
 
 
Abstract 
 
 
 
 
 
 
 
Vulvodynia is a chronic condition which affects an increasing number of women; it 
presents currently an incidence that is higher than had previously been estimated. Regarding 
pathogenesis, several (hormonal, infectious, inflammatory and psychological) factors have 
been proposed, but vulvodynia etiology remains still unclear. This disorder is a 
multifactorial condition with a significant impact on the patient’s quality of life, yet is 
difficult to diagnose (an under-estimated/ under-recognized affection). Certain medical 
investigations are required in order to exclude other diseases (the diagnosis of vulvodynia 
being one of exclusion), but anamnesis and physical examination are essential steps in the 
diagnosis.  
Although many therapies have been proposed, both pharmacological and non-
pharmacological, a standardized therapy has not yet been established/ generally accepted. 
Accordingly, many therapeutic options have been studied with varying results. Vulvodynia 
remains a challenging disease and a multidisciplinary approach is needed to achieve 
satisfactory outcomes. Further studies are needed to completely understand its pathogenesis 
and to develop a standardized treatment. 
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Introduction 
Vulvodynia (vulvar pain) is a chronic 
condition affecting 9-12% of women and reported 
in women aged 16 to 80 (1). Ethnic differences 
have been observed, vulvodynia being more 
frequently encountered in Caucasians than blacks 
(2). Most commonly patients complain of a burning 
sensation in the vulvar region (3). Vulvodynia 
represents an important public health issue; in the 
United States, the cost of treating these patients 
varies between 31 and 72 billion dollars annually 
(4).  
For a long time vulvodynia was not clearly 
defined. In 1976 the term “burning vulva 
syndrome” was used, but in 2003, it was replaced 
with the term “vulvodynia” by the International 
Society for the Study of Vulvovaginal Disease- 
ISSVD (5). According to the definition of the 
ISSVD, vulvodynia is a chronic pain localized in 
the vulvar area which lasts more than 3 months 
without a proven etiology. Several types of 
vulvodynia are described: provoked vulvodynia 
(caused by direct touch, inserting a tampon, or 
sexual touch) localized especially by the vaginal 
vestibule, unprovoked vulvodynia (occurring 
without touch or contact) and, mixed vulvodynia. It 
may be considered „generalized,” as when the 
symptoms involve the whole area of the vulva, or 
localized to the clitoral area (clitorodynia) or to the 
vestibule (vestibulodynia) (4, 6). Recently, in April 
2015 a classification of chronic vulvar pain was 
competed which indicates that the vulvar pain may 
have a specific cause (inflammation, trauma, 
neoplasm) or may be idiopathic, in which case the 
term of vulvodynia should be used (4, 7).  
 
Discussion  
Pathogenesis  
The pathogenic mechanism of vulvodynia is 
not fully understood. Over time, several theories 
have been postulated, which have attributed roles to 
hormonal, infectious/ inflammatory, and 
psychological factors in its pathogenesis (8).  
 Role of infections. Inflammatory response 
developed as a consequence of genitourinary 
infections may be involved in the occurrence of 
vulvodynia. For instance, in women with vaginal 
infection due to Trichomonas, pro-inflammatory 
markers such as IL6, IL8 and TNF alpha were 
identified. In another study, a group of women with 
vulvodynia was compared with a group of healthy 
women and it was observed that a significantly 
higher percentage of those with vulvodynia were 
infected with strains of human papilloma virus 
(HPV) (8). Some authors consider that vulvodynia 
may occur due to hypersensitivity to various species 
of Candida (9). However no study has revealed a 
link between any infectious agent and the 
development of vulvodynia.  
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 Neuro-inflammatory hypothesis. In some cases of 
vulvodynia histopathological examination displayed 
an inflammatory infiltrate consisting mainly of mast 
cells; in other cases a reduced number of mast cells 
was seen or the inflammatory infiltrate was not 
identified. With respect to the mediators of 
inflammation, pro-inflammatory cytokines and 
vulvovaginal neurokine CGRP were revealed. Thus, 
the hypothesis of a neuro-inflammatory process 
involved in the vulvodynia pathogenesis was 
suggested (10).  
 Hyperinnervation. Many studies analysed the 
number of nerve fibers in the vulvar area and the 
presence of hypersensitivity. A large number of 
nerve endings acting as nociceptors were observed, 
which may explain the allodynia experienced by 
those women. A high sensitivity to different stimuli 
(tactile, thermic) was revealed especially in the 
patients with provoked vulvodynia (4). In addition, 
patients with vulvodynia have lower pain thresholds 
than healthy women. Somatosensory changes were 
detected mainly in the vestibular area (10).  
 Muscles dysfunction. A role in the pathogenesis of 
vulvodynia has been attributed to pelvic floor 
muscle dysfunction. Electromyographic studies 
have shown increased muscle tonus and impaired 
relaxation in these patients (10).  
 Hormonal factors. Several authors have described 
an association between the use of oral 
contraceptives and vulvodynia, but others have 
refuted this hypothesis (11). The study of Bazin et 
al. revealed that women who had used oral 
contraceptives before age 17 had a higher risk of 
developing vulvodynia. However the study has as a 
limitation a low number of women who did not use 
oral contraceptives (12).  
 Psychological factors. In terms of psychological 
factors, vulvodynia is identified more commonly in 
women with an altered psychological status, those 
with sleep disorders, with posttraumatic stress or 
suffering from chronic pain (2). Several studies 
have highlighted that the women with vulvodynia 
associate different conditions characterized by 
chronic pain such as fibromyalgia, irritable bowel 
syndrome, interstitial cystitis, and 
temporomandibular joint disorders (13, 14).  
 Diagnosis  
The first symptoms may occur after the first 
sexual contact or later, and in some cases in 
childhood. Anamnesis and clinical examination are 
very important to differentiate between organic 
chronic pain and vulvodynia. The anamnesis should 
include information about the patient’s sexual 
behaviour, local hygiene, and clothing. Many times 
a correct diagnosis is achieved later, after many 
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visits to different doctors; in some cases it may take 
several years. Diagnosis of vulvodynia should 
remain a diagnosis of exclusion. Vulvodynia most 
commonly occurs in women aged 20 to 40. A 
higher incidence has been observed in Hispanics. 
The pain varies in intensity and may be described as 
a burning sensation or as a pruritus, or it may have 
an irritative character. Erythema may be noticed 
especially in the vestibular area and around the 
Bartholin glands (15-17).  
In order to identify the sensitive vulvar area a 
cotton swab should be used. Commonly the higher 
sensitive area is identified in the posterior introitus 
and the posterior hymenal remnants. A thorough 
genitourinary examination should be performed in 
order to rule out other conditions such as infections 
or trauma. In addition, the patients should be 
referred to a gynaecologist and undergo a 
colposcopy. An examination of the vaginal 
secretion to rule out an infection should also be 
carried out (15, 18).  
The most common form is localized provoked 
vulvodynia. Patients having this form report an 
intense and long-lasting pain, provoked by a touch, 
in a certain region, while no pain is felt in other 
regions. Patients state that the symptoms (pain, 
burning) may last for several hours. In addition, 
they present dysuria, difficulty in using tampons 
and often interrupt the sexual acts due to 
dyspareunia (19).  
It was observed that remission of the 
symptoms may occur in 10% of cases, even without 
treatment and it seems to be related to the onset of 
the disease. Therefore vulvodynia is primary when 
the onset is at the time of sexual debut or first 
tampon insertion, and secondary when the 
symptoms occur later. The remission occurs most 
commonly in secondary vulvodynia, a fact that 
suggests that a different etiopathogenic mechanism 
may be involved. Analyzing tissue from the 
involved areas, studies have revealed that in 
primary vulvodynia the density of nerve fibers is 
higher and the degree of hyperplasia is greater (20). 
The main differential diagnoses are allergic 
vulvitis, chronic candida vulvovaginitis, lichen 
planus, lichen sclerosis, vaginismus and vulvar 
intraepithelial neoplasia (15).  
Treatment  
The first steps must focus on rules regarding 
hygiene and diet. The patient should avoid irritating 
products such as soaps and perfumes or alcohol- 
based creams and wear cotton clothes and use 
moisturizing creams. Studies have shown that a diet 
containing less oxalates and less simple 
carbohydrates may be useful. In addition, calcium 
citrate may be administered due to its role in 
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decreasing the oxalate deposits in the skin (1,21). In 
many cases vulvodynia is not diagnosed and 
appropriately treated (22). Since the etiology of the 
disease is unknown and many mechanisms were 
supposed to be involved, the treatment is empirical 
and includes various methods, pharmacological and 
non-pharmacological. The approach to the patient 
should be multidisciplinary (3, 23).  
Topical treatment  
Topical lidocaine 5% is the most common 
drug administered in patients with vulvodynia. 
Lidocaine through its anesthetic effect decreases 
hypersensitivity. It is best applied in the evening or 
before intercourse to relieve pain and discomfort. 
Haefner et al. have revealed significant 
improvement of symptoms after 7 weeks of 
treatment (24).  
Some authors have emphasized the efficacy of 
topical capsaicin. This approach has the 
disadvantage of causing discomfort on the 
application area, being discontinued by patients in 
most cases (11). Estrogen cream may be applied 
especially in premenopausal women, but studies 
have shown a variable efficacy (16).  
The effectiveness of cromolyn in the 
treatment of vulvodynia is controversial—in one 
study results were no better than those of a placebo 
group (25). Its mechanism of action is based on the 
decrease of mast cells degranulation (15). 
Corticosteroids may be useful if they are 
administered intralesionally; topical administration 
did not prove effective (11).  
Other topical therapies reported in some 
studies as effective are nitroglycerin, amitriptyline 
2% in combination with baclofen 2% and topical 
antifungal agents (24).  
Systemic treatment  
Tricyclic antidepressants, drugs used in 
neuropathic pain, are often the first-line medication 
in vulvodynia. Amitriptyline and desipramine are 
most commonly used (21). However Leo et al. have 
analysed the available studies on vulvodynia and 
found no sufficient evidence to support their 
administration in vulvodynia (26). Tricyclic 
antidepressants act by blocking the reuptake of 
noradrenalin and serotonin. Serotonin inhibitors, 
which are also administered in neuropathic pain, 
have been suggested as a therapeutic option, but 
their effectiveness is still questionable, more useful 
being selective serotonin and norepinephrine 
reuptake inhibitors (9).  
The systemic medication also includes 
anticonvulsant drugs, gabapentin and 
carbamazepine, with success rate reported between 
50 and 82%. However further studies are needed to 
demonstrate the efficacy of this drug class (24, 27).  
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Surgery  
In the case of localized pain, surgery may 
represent a therapeutic option. Studies have 
revealed that up to 80% of patients who undergo 
vestibuloectomy report the remission of the disease 
(21). Nevertheless this method should be reserved 
for very serious cases (15). The recurrences are 
common on the remaining vulvar tissue (21).  
Other treatments  
Psychological and psychosexual therapies 
play an important role in the management of 
patients with vulvodynia. Besides basic counseling 
which may be performed by any physician and 
consists of reassuring the patient that she has no any 
underlying disease, cognitive behavioural therapy 
may be used with significant benefits, according to 
some studies (3, 28). Psychosexual therapy may be 
useful in order to improve the sexual contact, 
requiring several sessions which are best carried out 
with the patient’s partner present (3).  
Although physical therapy is not a 
standardized treatment, it may be effective. Physical 
therapy includes active exercises for the pelvic 
girdle and floor, soft tissue mobilization and joint 
manipulation, electrical stimulation, and bladder 
and bowel retraining (16, 24). It has been observed 
that patients with vulvodynia have associated 
hypertonia of the pelvic floor (11).  
Several studies have shown the beneficial role 
of botulinum toxin in the treatment of vulvodynia. 
Botulinum toxin inhibits the release of substance P 
and glutamate from nociceptive neurons (29, 30). 
The impact of vulvodynia on the quality of life 
Vulvodynia has a significant impact on the 
patient’s quality of life (31). Khandker et al. have 
shown that patients with vulvodynia often exhibit 
psychiatric disorders such as anxiety and 
depression; at the same time vulvodynia represents 
a risk factor for developing such disorders. (32). It 
has been observed that the disease has a major 
social and emotional impact, limiting work-related 
activities as well as leisure. In addition, these 
women are sad and frustrated (33). 
Patients with vulvodynia report a decrease in 
sexual desire, in sexual satisfaction and frequency 
of sexual acts. In addition, patients are more 
distressed about their body image (4, 34).  
 
Conclusions  
Vulvodynia is a disorder difficult to diagnose, 
with an incidence higher than previously thought. It 
is a multifactorial condition having a significant 
impact on the patient’s quality of life. The diagnosis 
is one of exclusion, requiring further investigations. 
Many therapeutic options have been studied with 
varying results. Vulvodynia remains a challenging 
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disease and a multidisciplinary team is needed to 
achieve satisfactory outcomes. Further studies are 
needed to completely understand its pathogenesis 
and to work out a standardized treatment.  
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